It was a busy year for the Indiana life sciences community, with a flurry of billion-dollar deals, major announcements, and a few setbacks. Here we present the top 10 stories of 2023—the good, the bad and the ugly—about an industry that is often hailed as a key driver of Indiana’s economy.
RayzeBio is building a large factory on the northwest side of Indianapolis to make radioisotopes for cancer treatment.
History: The Chevrolet Silverado, the second-most-popular pickup truck in America last year, is made at General Motors Co.’s Fort Wayne Assembly Plant. The 3-million-square-foot facility was built in 1986 and today employs nearly 4,000 people. GM has invested $1.2 billion in the plant, which recently celebrated manufacturing its 10 millionth truck. In June, GM announced […]
Fauna Bio, based in the San Francisco area, said Thursday it will give Lilly access to its AI platform, called Convergence, to support preclinical drug discovery efforts in obesity.
The investment in Sudo Biosciences, a three-year-old Carmel biotech, is one of the largest in recent years for an Indiana-based science startup, a signal that investors are attracted by its work on a class of drugs to treat autoimmune and inflammatory diseases.
Community Health Network has agreed to pay the United States government $345 million to settle allegations that it engaged in a years-long scheme to recruit physicians and pay them huge salaries and bonuses in return for “downstream referrals” on medical procedures.
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
VillageMD, a subsidiary of Chicago-based pharmacy giant Walgreens Boots Alliance, is closing more than 60 primary care clinics in five markets, including nine practices in northern Indiana and four in central Indiana.
The new drug, called Zepbound, carries a hefty price of $1,059.87 per month, and insurers and health care plans are balking, questioning its affordability. Many employers and government health programs exclude obesity treatments from their coverage.
The city wants to build a “housing hub” that will include the city’s first low-barrier homeless shelter on 11 parcels at the intersection of Shelby and East Georgia streets.
The company, Carmot Therapeutics, has numerous drugs under development. Its lead asset is a once-a-week injection that is in mid-stage development for the treatment of obesity.
In March, Eskenazi Health launched a fundraising campaign to help it move the needle on health disparities. As of last month, its foundation had raised $57 million.
Speaking at Monday’s Economic Club of Indiana, Corteva CEO Chuck Magro said last year’s decision was anything but hasty or haphazard.
The two companies have been battling for years over patents for migraine headache drugs—Emgality for Lilly and Anjovy for Teva. Both drugs are once-monthly injections and were approved 13 days apart in September 2018.
The utility’s initial proposal provoked widespread objections, including from more than 40 customers who attended two field hearings.
The live-work-play campus has been picked to join a new national network designed to connect researchers, entrepreneurs and investors to accelerate the development of health care products and services and speed up health care innovations.
The Indianapolis-based philanthropy giant says the grants are intended to help immigrants acclimate to life in central Indiana and make progress toward self-sufficiency.
The Bloomington plant, with about 1,000 employees, is the fifth-largest employer in Monroe County, according to the Greater Bloomington Chamber of Commerce, and is poised for more growth.
Some warn that the spiraling number of deals could lead to large physician groups having an unfairly high market share, which could lead to price increases and cost-cutting.
The extension comes amid pushback from several investors, including Point’s largest institutional stock holder.
